Vanhanen H T, Blomqvist S, Ehnholm C, Hyvönen M, Jauhiainen M, Torstila I, Miettinen T A
Second Department of Medicine, University of Helsinki, Finland.
J Lipid Res. 1993 Sep;34(9):1535-44.
A randomized double-blind study was made in 67 modestly hypercholesterolemic subjects by replacing 50 g of daily dietary fat by the same amount of a rapeseed oil preparation without and with fat-soluble sitostanol esters. The diet became relatively rich in dietary fat (37%) especially in subjects with a low basal calorie intake. The esters were prepared by transesterification of sitostanol with rapeseed oil fatty acids. The effects of sitostanol esters were studied on serum cholesterol and cholesterol synthesis (measuring cholesterol precursors in serum) and absorption (measuring serum plant sterols). The results were related to different apoE phenotypes. A 6-week regimen of about 3.4 g/day of sitostanol lowered total and low density lipoprotein (LDL) cholesterol levels by 7.5% and 10%, respectively, over that due to rapeseed oil alone. High density lipoprotein (HDL) cholesterol and triglyceride concentrations were unchanged. Thus, the HDL/LDL cholesterol ratio was significantly increased. The decrease in LDL cholesterol level was more consistent in subjects with the epsilon 4 allele than in those with homozygous epsilon 3 alleles. Sitostanol markedly decreased serum campesterol (-46%) and sitosterol (-30%), especially in subjects with the epsilon 4 alleles known to have high cholesterol absorption . The decreases of LDL cholesterol and plant sterols were interrelated, suggesting that reduced cholesterol absorption contributed to the lowering of LDL cholesterol. Serum sitostanol was unchanged, while the serum cholesterol precursors, delta 8-cholestenol, desmosterol, and lathosterol, were compensatorily increased by 10% (P < 0.05), most consistently in the subjects with epsilon 4 alleles, indicating an increase in cholesterol synthesis. The study demonstrates that sitostanol esters dissolved in dietary fat can be recommended for treatment of modest primary hypercholesterolemia and are apparently practical and suitable for cholesterol lowering in a general population.
对67名中度高胆固醇血症患者进行了一项随机双盲研究,用等量的含或不含脂溶性谷甾烷醇酯的菜籽油制剂替代每日50克膳食脂肪。饮食中脂肪含量相对增加(37%),尤其是基础热量摄入较低的受试者。这些酯是通过谷甾烷醇与菜籽油脂肪酸的酯交换反应制备的。研究了谷甾烷醇酯对血清胆固醇、胆固醇合成(测量血清中的胆固醇前体)和吸收(测量血清植物甾醇)的影响。结果与不同的载脂蛋白E表型相关。每天约3.4克谷甾烷醇的6周疗程使总胆固醇和低密度脂蛋白(LDL)胆固醇水平分别比单独使用菜籽油降低了7.5%和10%。高密度脂蛋白(HDL)胆固醇和甘油三酯浓度未发生变化。因此,HDL/LDL胆固醇比值显著升高。与纯合子ε3等位基因的受试者相比,携带ε4等位基因的受试者LDL胆固醇水平的降低更为一致。谷甾烷醇显著降低了血清菜油甾醇(-46%)和甾醇(-30%),尤其是在已知胆固醇吸收较高的携带ε4等位基因的受试者中。LDL胆固醇和植物甾醇的降低是相互关联的,这表明胆固醇吸收减少有助于降低LDL胆固醇。血清谷甾烷醇未发生变化,而血清胆固醇前体,如δ8-胆甾烯醇、羊毛甾醇和粪甾醇则相应增加了10%(P<0.05),在携带ε4等位基因的受试者中最为一致,这表明胆固醇合成增加。该研究表明,溶解在膳食脂肪中的谷甾烷醇酯可推荐用于治疗中度原发性高胆固醇血症,显然切实可行且适合于普通人群降低胆固醇。